Dernièrement…

Welcome @AmoebaNature as a featured exhibitor at the BioSolutions Conference & Expo!

Amoéba is an innovative #greentech company providing the industry with disruptive & sustainable solutions for key resource treatment. Learn more at http://ow.ly/icPi50Mzv8N

#BioSolutions

📣 Communiqué de presse : https://bit.ly/3RbfQHe
#Amoéba annonce l’annulation de l’émission de la 8° tranche optionnelle d’OCA et la signature d’un contrat avec Redbridge Debt and Treasury Advisory afin d’adapter sa stratégie financière aux enjeux de transformation industrielle

📣 Communiqué de presse : https://bit.ly/3X2hdKt
#Amoéba confirme son éligibilité au dispositif PEA-PME. Les #actions AMOEBA peuvent donc être intégrées dans les portefeuilles PEA PME, dédiés aux #investissements dans les #PME et #ETI selon les critères réglementaires.

🎥 @Fabrice Plasson, PDG d’#Amoéba, revient sur cette année exceptionnelle dans une vidéo dédiée au #bilan 2022 et aux #perspectives 2023. AMM, nouvelle usine, stratégie, plan de financement, tant de sujets abordés sur la chaîne #YouTube d’#Amoéba : https://bit.ly/3Wz75bz

Amoéba : Publication of the 2021 Universal Registration Document

Amoéba announces the availability of the 2021 Universal Registration Document including the Annual Financial Report

Lyon (France), April 13, 2022 -8.30 am- AMOÉBA (FR0011051598 – ALMIB), producer of a biological
biocide capable of eliminating bacterial risk in water and human wounds, and a biocontrol product
for plant protection, still in a development phase, announces that the 2021 Universal Registration
Document was filed with the French Financial Markets Authority (Autorité des marchés financiers AMF) on April 12, 2022 under number D.22-0280.

The 2021 Universal Registration Document includes:

  • the Annual Financial Report comprising the consolidated financial statements, the parent
    company financial statements, the management report and the related statutory auditors’
    reports
  • the Board of Directors’ corporate governance report.

The Universal Registration Document 2021 also presents the company’s activities, particularly in the
development of the biocidal and biocontrol applications and its research works. The organisation,
financial situation, results and prospects of Amoéba are also described in the Document.

The document may be viewed or downloaded on the company’s website www.amoeba-nature.com
under section “Investors / financial documents/ Reference Document”. Copies of the Universal
Registration Document are also available at the company’s headquarters: 38, avenue des frères
Montgolfier, 69680 Chassieu, France.